These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29211833)

  • 1. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
    Fushimi C; Tada Y; Takahashi H; Nagao T; Ojiri H; Masubuchi T; Matsuki T; Miura K; Kawakita D; Hirai H; Hoshino E; Kamata S; Saotome T
    Ann Oncol; 2018 Apr; 29(4):979-984. PubMed ID: 29211833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined androgen blockade for salivary gland carcinoma.
    Gourd E
    Lancet Oncol; 2018 Jan; 19(1):e17. PubMed ID: 29233558
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
    Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
    Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
    Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
    Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
    Soper MS; Iganej S; Thompson LD
    Head Neck; 2014 Jan; 36(1):E4-7. PubMed ID: 23720164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
    Yamamoto N; Minami S; Fujii M
    Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
    Amato R; Stepankiw M; Gonzales P
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1629-34. PubMed ID: 23604530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
    Locati LD; Perrone F; Cortelazzi B; Imbimbo M; Bossi P; Potepan P; Civelli E; Rinaldi G; Quattrone P; Licitra L; Pilotti S
    Cancer Biol Ther; 2014 Jun; 15(6):678-82. PubMed ID: 24618694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
    Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T
    Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
    Jeong ISD; Moyers J; Thung I; Thinn MM
    Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study.
    Okada T; Saotome T; Nagao T; Masubuchi T; Fushimi C; Matsuki T; Takahashi H; Miura K; Tsukahara K; Tada Y
    In Vivo; 2019; 33(3):843-853. PubMed ID: 31028207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
    Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
    Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
    J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
    [No Abstract]   [Full Text] [Related]  

  • 15. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
    Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
    [No Abstract]   [Full Text] [Related]  

  • 16. Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.
    Honma Y; Monden N; Yamazaki K; Kano S; Satake H; Kadowaki S; Utsumi Y; Nakatogawa T; Takano R; Fujii K; Koroki Y; Aoyama J; Ouchi S; Ogawa T; McCarthy S; Brookman-May SD; Mundle S; Li J; Thaper D; Nagao T; Tada Y
    Clin Cancer Res; 2024 Aug; 30(16):3416-3427. PubMed ID: 38940667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
    van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
    Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C
    J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial [
    Boers J; Venema CM; de Vries EFJ; Hospers GAP; Boersma HH; Rikhof B; Dorbritz C; Glaudemans AWJM; Schröder CP
    Eur J Cancer; 2021 Feb; 144():151-161. PubMed ID: 33341447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
    Yeoh CC; Dabab N; Rigby E; Chhikara R; Akaev I; Gomez RS; Fonseca F; Brennan PA; Rahimi S
    J Oral Pathol Med; 2018 Aug; 47(7):691-695. PubMed ID: 29863801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.